WNT3A and prostate carcinoma: Treatment of prostate cancer cells with Wnt3A CM or purified recombinant Wnt3A protein significantly enhanced cell growth and migration [31], [32], while treatment of prostate cancer cells with the LRP6 antagonist Dkk1 significantly inhibited cell growth and migration [32].